Changes in global patterns of care for first-line advanced nonsquamous (NS) non-small cell lung cancer (NSCLC): 2007-2010

被引：0
|
作者：
Combest, A. J.
Bryan, J. K.
Moseley, A.
Reitsma, D. J.
Scazafave, M.
Wood, J. M.
Iocca, H. A.
Goyo, J.
An, J. S.
Lee, M. W.
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[2] PPD Inc, Wilmington, NC USA
[3] Synovate Healthcare, Mahwah, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16639
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine
    Zhang, X.
    Zhou, Q.
    Song, Y.
    Chen, G. Y.
    Zhong, D. S.
    Yu, Z.
    Yu, P.
    Zhang, Y. P.
    Chen, J. H.
    Hu, Y.
    Feng, G. S.
    Song, X.
    Shi, Q.
    Yang, L. L.
    Zhang, P. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [3] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2015, 26
  • [4] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [6] Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer
    Gentzler, Ryan D.
    Patel, Jyoti D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (06): : 889 - 897
  • [7] First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC)
    Mekhail, Tarek
    Waterhouse, David Michael
    Hadley, Terence J.
    Webb, Charles D.
    Burris, Howard A.
    Hainsworth, John D.
    Greco, F. Anthony
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [9] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [10] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
    Wang, Lin
    Liu, Ting
    Lin, Xihan
    Zhang, Yu
    Shi, Luwen
    You, Ruxu
    Liu, Jinyu
    IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226
12345